Anti-lung Cancer Marine Compounds: A Review - Therapeutic Innovation & Regulatory Science
Source : https://link.springer.com/article/10.1007/s43441-022-00375-3
Lung cancer is one of the most common and lethal cancers in human beings. Lung cancer has been divided into two major types: small cell lung cancer (SCLC) and non-small...
Conclusion/Relevance: This review compares the diversity of marine-derived bioactive compounds from different marine species. Some of the natural products from marine resources are in different stages of clinical trials. By the way, most of them have been studied in vitro and in vivo. Additionally, in this review, the mechanisms of action of...
Fusion-positive non-small cell lung carcinoma: Biological principles, clinical practice and diagnostic implications - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34997651/
Based on superior efficacy and tolerability, targeted therapy is currently preferred over chemotherapy and/or immunotherapy for actionable gene fusions that occur in late stage non-small cell lung carcinoma (NSCLC). Consequently,...
Conclusion/Relevance: The purpose of this review is to focus on recent data concerning the main gene fusions identified in NSCLC, followed by the discussion of major challenges in this domain.
Contouring cardiac substructures on average intensity projection 4D-CT for lung cancer radiotherapy: a proposal of a heart valve contouring atlas - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34990727/
1 Department of Radiotherapy, Military Institute of Medicine, Warsaw, Poland; Department of Radiotherapy, Regional Oncology Centre, Czestochowa, Poland. Electronic address: [email protected]. 2 Department of Radiotherapy, Medical Physics Unit, Military Institute...
Conclusion: Our atlas enables reproducible delineation of the heart valves. Delineation of the heart and its substructures on AVE-4D-CT scans is feasible, with inter-observer variability similar to that reported on conventional non-contrast CT scans.
Elucidation of optimal proteinuria management based on the risk of ramucirumab‑induced proteinuria
Source : https://www.spandidos-publications.com/10.3892/ol.2021.13163
Proteinuria is a dose‑limiting adverse effect of ramucirumab treatment, which is an anti‑angiogenic agent that targets the human vascular endothelial growth factor. The predictors of proteinuria have not been completely...
Conclusion/Relevance: The results from the present study indicated that particular attention should be paid to proteinuria at the start of treatment when monitoring proteinuria as an adverse event of ramucirumab treatment.
Patterns of Care in Maintenance Therapy in US Patients Undergoing Definitive Chemoradiation for Stage 3 Non-Small Cell Lung Cancer (NSCLC) - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34991107/
The rate of durvalumab utilization was overall low in both the open and closed claims data sources (31% and 53%, respectively). It remains unknown what percent of eligible patients end...
Conclusions: The rate of durvalumab utilization was overall low in both the open and closed claims data sources (31% and 53%, respectively). It remains unknown what percent of eligible patients end up receiving durvalumab, as our analysis was unable to filter out patients who were unfit for durvalumab or if they had progression after...